SCHEMBL2392699

SCHEMBL2392699

NC(=O)[C@@H](O)c1ccccc1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 2/20 0.55
FGFR1 P11362 2/20 0.43
FGFR2 P21802 2/20 0.43
FGFR4 P22455 2/20 0.43
FGFR3 P22607 2/20 0.43
SRC P12931 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
KMT2A Q03164 2/20 0.42
HNF4A P41235 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 2/20 0.39
HPGD P15428 1/20 0.39
BCL2L1 Q07817 1/20 0.39
LMNA P02545 3/20 0.38
HDAC4 P56524 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395264 1.00 BCAT2 (0.55) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL2395269 1.00 BCAT2 (0.55) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL9890802 0.86 SLC6A4 (0.44) BCAT2ALDH1A1CA12CA1CA2
SCHEMBL4886483 0.84 LMNA (0.50) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL12202853 0.82 CNR2 (0.43) BCAT2FGFR1ALDH1A1HSD17B10SMN1; SMN2
SCHEMBL2393221 0.82 SLC9A1 (0.42) FGFR1FGFR3MAPK1
SCHEMBL9890803 0.82 CHRM1 (0.46)
SCHEMBL2393200 0.81 APP (0.43) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL2393198 0.81 APP (0.43) BCAT2FGFR1FGFR2FGFR4FGFR3
SCHEMBL2391614 0.81 APP (0.43) BCAT2FGFR1FGFR2FGFR4FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
CN-102282124-A Biphenylacetamide derivative 2011-12-14 CN disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 BCAT2 248/4885FGFR1 294/4885FGFR2 139/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 BCAT2 248/4885FGFR1 294/4885FGFR2 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.